Dr. Abou-Alfa on the Role of Immunotherapy in HCC

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

The role of immunotherapy could be extending beyond systemic disease because there is interest in combining it with local therapy, explains Abou-Alfa.

There are preliminary data focused on a combination of local therapy and an immunotherapy regimen, which demonstrates a potential success, states Abou-Alfa.